LTI 03
Alternative Names: Caveolin-1 scaffold protein-derived 7-amino acid peptide; Caveolin-1 scaffolding protein derived peptide; CSP7; LTI-03Latest Information Update: 14 Oct 2025
At a glance
- Originator Lung Therapeutics; University of Texas at Tyler
- Developer Rein Therapeutics; University of Texas at Tyler
- Class Alcohols; Amides; Amino acids; Antifibrotics; Benzene derivatives; Carboxylic acids; Peptides
- Mechanism of Action Caveolin 1 replacements
-
Orphan Drug Status
Yes - Idiopathic pulmonary fibrosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis